The failure of a promising Alzheimer's drug in clinical trials highlights the gap between diagnosis - where real progress has recently been made - and treatment of the disease.
It was not just that the drug, made by Eli Lilly, did not work - maybe that could be explained by saying the patients' illness was too far advanced when they received it. It was that the drug actually made them worse, the company said. And the larger the dose they took, the worse were patients' symptoms of memory loss and inability to care for themselves. Not only that, the drug also increased the risk of skin cancer.
Read more: Doubt on Tactic in Alzheimer's Battle